Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 22, 2026Journal of Neurology Neurosurgery & Psychiatry

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

IRIzanne RoosSSSifat SharminDHDana Horakova

Discussion

Loading...

Member takes

Overview

Observational cohort study compares ocrelizumab with other therapies in multiple sclerosis patients, highlighting efficacy differences.

Key Points

  • The study aims to compare the effectiveness of ocrelizumab against other treatments for multiple sclerosis across various patient subgroups.
  • Identified patients from MSBase, OFSEP, and Danish MS Registry treated with ocrelizumab, fingolimod, natalizumab, or alemtuzumab for at least 6 months.
  • Conducted pairwise comparisons of relapse rates and progression in clinicodemographic subgroups.
  • Analyzed annualized relapse rates and relapse-associated worsening using statistical methods.
  • Fingolimod had a higher annualized relapse rate (0.14 vs 0.06, p<0.001) and increased relapse risk (HR 2.26, 95% CI 1.98 to 2.58) compared to ocrelizumab.
  • Natalizumab showed a marginally higher relapse rate (0.10 vs 0.07, p<0.001) than ocrelizumab, while alemtuzumab also had a higher rate (0.18 vs 0.12, p<0.001).
  • Ocrelizumab was superior to both natalizumab and alemtuzumab in controlling relapses, especially in patients who were not treatment-naïve.

Cite This Study

Roos et al. (2026) studied this question.

synapsesocial.com/papers/6a0ff3ecd674f7c03778cd28https://doi.org/10.1136/jnnp-2026-338424
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of Ocrelizumab in comparison to placebo for multiple sclerosis: A systematic review and meta-analysis2025
  2. 2A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis2024 · 10 citations
  3. 3Long‐Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real‐World Longitudinal Study2026 · 1 citations
  4. 4Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis2024 · 4 citations
  5. 5Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis2024 · 22 citations